GlobeNewswire latest releases

Local Non-Profit Hoping to Make a Difference During the Holiday Season

Retrieved on:

Friday, December 2, 2022

The JL Cares Leadership team also seeks out partnerships with other local businesses to make a greater impact than they could by themselves.

Key Points:

The JL Cares Leadership team also seeks out partnerships with other local businesses to make a greater impact than they could by themselves.
With the rising prices in the cost of goods, the team hopes it can make a difference in the lives of a few.
To nominate a family, visit jlcares.org and tell the team how JL Cares can make a difference in the lives of a family.
JL Remodeling's owner, Jeff Laurence has a passion towards helping people, and launched the JL Cares non-profit in 2021.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Generac Holdings (GNRC) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Filed

Retrieved on:

Friday, December 2, 2022

Electricity, Person, Fraud, Book, NYSE, Bankruptcy, News, Safety, SAN, Steve Berman (lawyer), GNRC, Renewable energy, Pharmaceutical industry, Generac Holdings

SAN FRANCISCO, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Generac Holdings Inc. (NYSE: GNRC) investors who suffered significant losses to submit your losses now .

Key Points:

SAN FRANCISCO, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Generac Holdings Inc. (NYSE: GNRC) investors who suffered significant losses to submit your losses now .
Each of these disclosures caused the price of Generac shares to decline sharply, thereby injuring investors.
Were focused on investors losses and proving Generac cooked its books, said Reed Kathrein, the Hagens Berman partner leading the investigation.
If you invested in Generac and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .

GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Schmitt Industries, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important December 12 Deadline in Securities Class Action Filed by the Firm – SMIT

Retrieved on:

Friday, December 2, 2022

Titan, Court, Class, SMIT, Advertising, I-Space (Chinese company), Insurance, Tobacco

WHAT TO DO NEXT: To join the Schmitt Industries class action, go to https://rosenlegal.com/submit-form/?case_id=8823 or call Phillip Kim, Esq.

Key Points:

WHAT TO DO NEXT: To join the Schmitt Industries class action, go to https://rosenlegal.com/submit-form/?case_id=8823 or call Phillip Kim, Esq.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Power Solutions International Announces Extension to $50 Million Shareholder Loan Agreement With Weichai America

Retrieved on:

Friday, December 2, 2022

Exercise, Gasoline, Transport, CHP, Acceleration, Natural gas, Annual report, Biofuel, Propane, COVID-19, Standard Chartered, PSI, Engineering, SOFR, USAO, OTC Markets Group, WOOD, Security (finance), Risk management

Borrowings under the Third Shareholders Loan Agreement will incur interest at the applicable Secured Overnight Financing Rate (SOFR), plus 4.65% per annum.

Key Points:

Borrowings under the Third Shareholders Loan Agreement will incur interest at the applicable Secured Overnight Financing Rate (SOFR), plus 4.65% per annum.
Further, if the applicable term SOFR is negative, the interest rate per annum shall be deemed as 4.65% per annum.
If the interest rate for any loan under the Third Shareholders Loan Agreement is lower than Weichais borrowing cost, the interest rate for such loan shall be equal to Weichais borrowing cost plus 1%.
Power Solutions International, Inc. (PSI) is a leader in the design, engineering and manufacture of a broad range of advanced, emission-certified engines and power systems.

Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022

Retrieved on:

Friday, December 2, 2022

Webcast / Conference Call Information:

Key Points:

Webcast / Conference Call Information:
The conference call can be also accessed by dialing +1 929 205 6099 for participants in the U.S. using the Webinar ID: 815 1815 0021 reference passcode 279853.
A replay of the conference call will also be available on Anavexs website for up to 30 days.
ANAVEX2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors.
All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Parex Resources to Hold Investor Presentation in Bogotá, Colombia

Retrieved on:

Friday, December 2, 2022

Toronto Stock Exchange, Corporation, Webcast, PXT, Composite, EST, Parex Bank, Capital market, MST, TSX, Management, New Ventures

CALGARY, Alberta, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Parex Resources Inc. (Parex or the Company) (TSX: PXT) will hold an investor presentation on December 6, 2022, beginning at 1:30 pm EST (11:30 am MST) in Bogot, Colombia.

Key Points:

CALGARY, Alberta, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Parex Resources Inc. (Parex or the Company) (TSX: PXT) will hold an investor presentation on December 6, 2022, beginning at 1:30 pm EST (11:30 am MST) in Bogot, Colombia.
The presentation will focus on the Companys strategy, operations, and future opportunities in Colombia.
Parex presenters will include:
Mike Kruchten Senior Vice President, Capital Markets & Corporate Planning
Katie Bernard Vice President, New Ventures
Ian Zapfe-Smith Vice President, Exploration
The presentation will be available via webcast.
Parex is the largest independent oil and gas company in Colombia, focusing on sustainable, conventional production.

PennantPark Floating Rate Capital Ltd. Announces Monthly Distribution of $0.095 per Share

Retrieved on:

Friday, December 2, 2022

Security (finance), The Company, Form 1099, RATE, NYSE, Investment, Exchange, Documentation, RIC, TASE, Life insurance, Iron ore

MIAMI, Dec. 02, 2022 (GLOBE NEWSWIRE) -- PennantPark Floating Rate Capital Ltd. (the "Company") (NYSE: PFLT) (TASE: PFLT) declares its monthly distribution for December 2022 of $0.095 per share, payable on January 3, 2023 to stockholders of record as of December 19, 2022.

Key Points:

MIAMI, Dec. 02, 2022 (GLOBE NEWSWIRE) -- PennantPark Floating Rate Capital Ltd. (the "Company") (NYSE: PFLT) (TASE: PFLT) declares its monthly distribution for December 2022 of $0.095 per share, payable on January 3, 2023 to stockholders of record as of December 19, 2022.
ABOUT PENNANTPARK FLOATING RATE CAPITAL LTD.
PennantPark Floating Rate Capital Ltd. is a business development company which primarily invests in U.S. middle-market private companies in the form of floating rate senior secured loans, including first lien secured debt, second lien secured debt and subordinated debt.
PennantPark Floating Rate Capital Ltd. is managed by PennantPark Investment Advisers, LLC.
PennantPark Floating Rate Capital Ltd. undertakes no duty to update any forward-looking statement made herein.

Athene Holding Ltd. Declares Fourth Quarter 2022 Preferred Stock Dividends

Retrieved on:

Friday, December 2, 2022

Security (finance)

Quarterly dividend of $396.875 per share on the companys 6.35% Fixed-to-Floating Rate Perpetual Non-Cumulative Preference Shares, Series A (the Series A Preference Shares); holders of depositary shares will receive $0.396875 per depositary share.

Key Points:

Quarterly dividend of $396.875 per share on the companys 6.35% Fixed-to-Floating Rate Perpetual Non-Cumulative Preference Shares, Series A (the Series A Preference Shares); holders of depositary shares will receive $0.396875 per depositary share.
Quarterly dividend of $351.5625 per share on the companys 5.625% Fixed Rate Perpetual Non-Cumulative Preference Shares, Series B (the Series B Preference Shares); holders of depositary shares will receive $0.3515625 per depositary share.
Quarterly dividend of $398.4375 per share on the companys 6.375% Fixed-Rate Reset Perpetual Non-Cumulative Preference Shares, Series C (the Series C Preference Shares); holders of depositary shares will receive $0.3984375 per depositary share.
Quarterly dividend of $304.6875 per share on the companys 4.875% Fixed Rate Perpetual Non-Cumulative Preference Shares, Series D (the Series D Preference Shares); holders of depositary shares will receive $0.3046875 per depositary share.

CalAmp Appoints Tech Finance Veteran, Jikun Kim, as SVP and Chief Financial Officer

Retrieved on:

Friday, December 2, 2022

Mr. Kim will serve as principal financial officer and principal accounting officer.

Key Points:

Mr. Kim will serve as principal financial officer and principal accounting officer.
Mr. Kim currently serves as Chief Financial Officer of Momentus, Inc., a Nasdaq-listed space infrastructure company, a position he has held since September 2020.
Prior to Momentus, from January 2019 to September 2020, Mr. Kim served as the Chief Financial Officer at Formlabs Inc., a 3D printer company.
Stolen Vehicle Recovery (SVR) business from CalAmp and holds an exclusive license to the LoJack mark in the United States and Canada.

FINWARD BANCORP ANNOUNCES FOURTH QUARTER DIVIDEND

Retrieved on:

Friday, December 2, 2022

Communication, Annual report, People's Bank, Federal Reserve Board of Governors, Growth, Bank

Finward Bancorps common stock is quoted on the NASDAQ Capital Marketunder the symbol FNWD.

Key Points:

Finward Bancorps common stock is quoted on the NASDAQ Capital Marketunder the symbol FNWD.
This press release may contain forward-looking statements regarding the financial performance, business prospects, growth, and operating strategies of Finward.
For these statements, Finward claims the protections of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
The forward-looking statements are based on managements expectations and are subject to a number of risks and uncertainties.

InterDigital Declares Regular Quarterly Cash Dividend

Retrieved on:

Friday, December 2, 2022

Multimedia, InterDigital, IDCC, Research

WILMINGTON, Del., Dec. 02, 2022 (GLOBE NEWSWIRE) -- InterDigital, Inc. (NASDAQ:IDCC), a mobile and video technology research and development company, today announced that its Board of Directors has declared a regular quarterly cash dividend of $0.35 per share on its common stock, payable on January 25, 2023, to shareholders of record at the close of business on January 11, 2023.

Key Points:

WILMINGTON, Del., Dec. 02, 2022 (GLOBE NEWSWIRE) -- InterDigital, Inc. (NASDAQ:IDCC), a mobile and video technology research and development company, today announced that its Board of Directors has declared a regular quarterly cash dividend of $0.35 per share on its common stock, payable on January 25, 2023, to shareholders of record at the close of business on January 11, 2023.
InterDigital develops mobile and video technologies that are at the core of devices, networks, and services worldwide.
InterDigital has licenses and strategic relationships with many of the worlds leading technology companies.
InterDigital is a registered trademark of InterDigital, Inc.

iBio Announces CEO Departure

Retrieved on:

Friday, December 2, 2022

NYSE American, Epitope, Computational biology, Chairperson, NYSE, Drug development, Acquisition, Fine chemical

It has been gratifying to have helped iBio through this dynamic and pivotal period of change, said Mr. Isett.

Key Points:

It has been gratifying to have helped iBio through this dynamic and pivotal period of change, said Mr. Isett.
Many thanks and best wishes for everyone at iBio in the continuing journey to help bring new and better treatments to people suffering with cancer.
iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases.
These forward-looking statements are based upon current estimates and assumptions and include statements regarding iBio continuing with a search for a new CEO.

Poet Technologies Announces Closing of C$4.4 Million Private Placement of Units

Retrieved on:

Friday, December 2, 2022

TORONTO, Dec. 02, 2022 (GLOBE NEWSWIRE) -- POET Technologies Inc. ("POET" or the "Corporation") (TSXV: PTK; NASDAQ: POET), the designer and developer of the POET Optical Interposer™, Photonic Integrated Circuits (PICs) and light sources for the data center, tele-communication and artificial intelligence markets, announces that it has completed its previously announced non-brokered private placement (the "Offering") of an aggregate 1,126,635 units of the Corporation (the "Units") at a price of C$3.81 (US$2.78) per Unit for aggregate gross proceeds of C$4,292,479.35 (US$3,132,045.30).

Key Points:

Each Warrant entitles the holder thereof to purchase one Common Share at an exercise price of C$4.95 (US$3.61) per Common Share for a period of three years following the closing date of the Offering.
Glen Riley, a director of the Corporation, subscribed for 10,000 Units under the Offering for gross proceeds of C$38,100 (US$27,800).
POETs Optical Interposer eliminates costly components and laborintensive assembly, alignment, burnin and testing methods employed in conventional photonics.
POET is headquartered in Toronto, with operations in Allentown, PA, Shenzhen, China and Singapore.

Guggenheim Energy & Income Fund Announces Tender Offer

Retrieved on:

Friday, December 2, 2022

Fund, Investment Company Act of 1940, Tender offer, Letter, Investment, GS, Securities Investor Protection Corporation, Sale, Guggenheim Partners, Liquidity, Financial adviser, Consultant, NAV, Eastern Time Zone, FUND, Insurance, Risk, Security (finance), Money transmitter

NEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Guggenheim Energy & Income Fund (the “Fund”) (XGEIX) announced today a tender offer to purchase for cash up to 2.5% of the Fund’s issued and outstanding common shares of beneficial interest (“common shares”). The tender offer will be conducted at a price equal to the Fund’s net asset value per common share on the date on which the tender offer expires. The Fund intends to commence the tender offer on or about Friday, December 2, 2022, with the expiration of the tender offer currently expected to take place on Tuesday, January 3, 2023 at 5:00 p.m., Eastern Time, unless otherwise extended.

Key Points:

NEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Guggenheim Energy & Income Fund (the Fund) (XGEIX) announced today a tender offer to purchase for cash up to 2.5% of the Funds issued and outstanding common shares of beneficial interest (common shares).
As soon as the tender offer commences, the Fund will file a tender offer statement on Schedule TO with the SEC, which will include an Offer to Purchase and related Letter of Transmittal.
Questions regarding the Tender Offer may be directed to Georgeson LLC, the information agent for the tender offer, at (888) 565-5190.
Guggenheim Investments represents the following affiliated investment management businesses of Guggenheim Partners, LLC: Guggenheim Partners Investment Management, LLC, Security Investors, LLC, Guggenheim Funds Distributors, LLC, Guggenheim Funds Investment Advisors, LLC, Guggenheim Partners Advisors, LLC, Guggenheim Corporate Funding, LLC, Guggenheim Partners Europe Limited, Guggenheim Partners Japan Limited, GS GAMMA Advisors, LLC, and Guggenheim Partners India Management.

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on:

Friday, December 2, 2022

CDK, Fast track (FDA), Financial compensation, Patient, Sale, Employment, SERD, Ribociclib, SAN, Pharmaceutical industry

These awards were approved by the Compensation Committee of Olemas Board of Directors and granted under the Company's 2022 Inducement Plan, with a grant date of December 1, 2022, as an inducement material to the new employee entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points:

These awards were approved by the Compensation Committee of Olemas Board of Directors and granted under the Company's 2022 Inducement Plan, with a grant date of December 1, 2022, as an inducement material to the new employee entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options are subject to the terms of the Olema Pharmaceuticals, Inc., 2022 Inducement Plan.
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for womens cancers.
Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts.